Transfected Stable Cell Lines
Reliable | High-Performance | Wide Rage
Precision reporter, kinase, immune receptor, biosimilar, Cas9, and knockout stable cell lines for diverse applications.
Transfected Stable Cell Lines
Reliable | High-Performance | Wide Rage
Precision reporter, kinase, immune receptor, biosimilar, Cas9, and knockout stable cell lines for diverse applications.
Premade Virus Particles
Ready-to-Use | High Titer | Versatile Applications
Premade AAV, adenovirus, lentivirus particles, safe, stable, in stock.
Virus-Like Particles (VLPs)
Stable | Scalable | Customizable
Advanced VLPs for vaccine development (Chikungunya, Dengue, SARS-CoV-2), gene therapy (AAV1 & AAV9), and drug screening (SSTR2, CCR5).
Oligonucleotide Products
Precise | High Yield | Tailored Solutions
Accelerate your research with cost-effective LncRNA qPCR Array Technology.
RNA Interference Products
Targeted | Potent | High Specificity
Human Druggable Genome siRNA Library enables efficient drug target screening.
Recombinant Drug Target Proteins
Authentic | Versatile | Accelerated
Providing functional, high-purity recombinant proteins—including membrane proteins and nanodiscs—to overcome bottlenecks in drug screening and target validation.
Clones
Validated | Reliable | Comprehensive Collection
Ready-to-use clones for streamlined research and development.
Kits
Complete | Convenient | High Sensitivity
Chromogenic LAL Endotoxin Assay Kit ensures precise, FDA-compliant endotoxin quantification for biosafety testing.
Enzymes
Purified | Stable | Efficient
Powerful Tn5 Transposase for DNA insertion and random library construction.
Aptamers
Highly Specific | Robust | Versatile
Aptamers for key proteins like ACVR1A, Akt, EGFR, and VEGFR.
Adjuvants
Enhancing | Synergistic | Effective
Enhance immune responses with high-purity, potent CpG ODNs.
Laboratory Equipment
Innovative | Reliable | High-Precision
Effortlessly streamline DNA extraction with CB™ Magnetic-Nanoparticle Systems.
Stable Cell Line Generation
Reliable | Scalable | Customizable
Fast proposals, regular updates, and detailed reports; strict quality control, and contamination-free cells; knockout results in 4-6 weeks.
Target-based Drug Discovery Service
Innovative | Comprehensive | Efficient
Target identification, validation, and screening for drug discovery and therapeutic development.
Custom Viral Service
Versatile | High-Yield | Safe
Unbeatable pricing, fully customizable viral packaging services (covering 30,000+ human genes, 200+ mammals, 50+ protein tags).
Custom Antibody Service
Precise | Flexible | Efficient
End-to-end antibody development support, from target to validation, enabling clients to rapidly obtain application-ready antibodies.
Antibody-Drug Conjugation Service
Integrated | Controlled | Translational
Comprehensive solutions covering design, development, and validation to ensure conjugated drugs with consistent quality and clinical potential.
Protein Degrader Service
Efficient | High-Precision | Advanced Therapeutics
Harness the power of protein degraders for precise protein degradation, expanding druggable targets and enhancing therapeutic effectiveness for cutting-edge drug discovery.
Nucleotides Service
Accurate | Flexible | High-Quality
Custom synthesis of oligonucleotides, primers, and probes for gene editing, PCR, and RNA studies.
Custom RNA Service
Custom RNA ServicePrecise | Flexible | GMP-ReadyCustom
RNA design, synthesis, and manufacturing—covering mRNA, saRNA, circRNA, and RNAi. Fast turnaround, rigorous QC, and seamless transition from research to GMP production.
Custom Libraries Construction Service
Comprehensive | High-throughput | Accurate
Custom cDNA, genomic, and mutagenesis libraries for drug discovery, screening, and functional genomics.
Gene Editing Services
Precise | Efficient | Targeted
Gene editing solutions for gene editing, knockouts, knock-ins, and customized genetic modifications. Integrated multi-platform solutions for one-stop CRISPR sgRNA library synthesis and gene screening services
Microbe Genome Editing Service
Precise | Scalable | Customizable
Enhance microbial productivity with advanced genome editing using Rec-mediated recombination and CRISPR/Cas9 technologies.
Biosafety Testing Service
Reliable | Comprehensive | Regulated
Complete biosafety testing solutions for gene therapy, viral vectors, and biologics development.
Plant Genetic Modification Service
Advanced | Sustainable | Tailored
Genetic modification for crop improvement, biotechnology, and plant-based research solutions.
Plant-based Protein Production Service
Efficient | Scalable | Customizable
Plant-based protein expression systems for biopharmaceuticals, enzyme production, and research.
Aptamers Service
Innovative | Fast | Cost-Effective
Revolutionizing drug delivery and diagnostic development with next-generation high-throughput aptamer selection and synthesis technologies.
CGT Biosafety Testing
Comprehensive | Accurate | Regulatory-compliant
Internationally certified evaluation system for biologics, gene therapies, nucleic acid drugs, and vaccines.
Pandemic Detection Solutions
Rapid | Precise | Scalable
Balancing accuracy, accessibility, affordability, and rapid detection to safeguard public health and strengthen global response to infectious diseases.
cGMP Cell Line Development
Reliable | Scalable | Industry-leading
Stable expression over 15 generations with rapid cell line development in just 3 months.
Supports adherent and suspension cell lines, offering MCB, WCB, and PCB establishment.
GMP mRNA Production
Efficient | Scalable | Precise
Scalable mRNA production from milligrams to grams, with personalized process design for sequence optimization, cap selection, and nucleotide modifications, all in one service.
GMP Plasmid Production
High Quality | Scalable | Regulatory-compliant
Our plasmid production services span Non-GMP, GMP-Like, and GMP-Grade levels, with specialized options for linearized plasmids.
GMP Viral Vector Manufacturing
Scalable | High Yield | Quality-driven
Advanced platforms for AAV, adenovirus, lentivirus, and retrovirus production, with strict adherence to GMP guidelines and robust quality control.
AI-Driven Gene Editing and Therapy
Innovative | Precision | Transformative
AI-powered one-click design for customized CRISPR gene editing strategy development.
AI-Antibody Engineering Fusion
Next-Generation | Targeted | Efficient
AI and ML algorithms accelerate antibody screening and predict new structures, unlocking unprecedented possibilities in antibody engineering.
AI-Driven Enzyme Engineering
Smart | Efficient | Tailored
High-throughput enzyme activity testing with proprietary datasets and deep learning models for standardized and precise enzyme engineering design.
AI-Enhanced Small Molecule Screening
Predictive | Efficient | Insightful
Leverage AI to uncover hidden high-potential small molecules, prioritize leads intelligently, and reduce costly trial-and-error in early drug discovery.
AI-Driven Protein Degrader Drug Development
Innovative | Targeted | Accelerated
Use AI-guided design to optimize protein degraders, addressing design complexity and enhancing efficacy while shortening development timelines.
| Cat.No. | Product Name | Price |
|---|
| Cat.No. | Product Name | Price |
|---|
| Cat.No. | Product Name | Price |
|---|
| Cat.No. | Product Name | Price |
|---|
Enoyl-CoA delta isomerase 1 (DCI) is an enzyme that plays a crucial role in lipid metabolism, specifically in the elongation of fatty acids.
DCI is a member of the enoyl-CoA delta isomerase family, which is characterized by the conversion of unsaturated fatty acids to their cis-delta-unsaturated derivatives. The enzyme is composed of two distinct domains: the N-terminal domain, which is responsible for the binding of the enzyme to the lipid substrates, and the C-terminal domain, which contains the catalytic center.
The N-terminal domain of DCI is responsible for the recognition and binding of the substrate, which is a crucial step in the catalytic process. This domain is highly conserved across different species and contains several motifs that are characteristic of lipid binding proteins. These include a conserved glycine-rich motif, a hydrophobic pocket, and a leucine zipper-like motif.
The C-terminal domain of DCI contains the catalytic center, which is responsible for the conversion of the substrate to its product. This domain is also highly conserved across different species and contains several motifs that are characteristic of lipid metabolizing enzyme. These include a conserved serine-rich motif, a cysteine-rich motif, and a conserved acidic patch.
The expression of DCI is regulated at multiple levels, including transcription, translation, and post-translational modification. The transcription of DCI is regulated by various transcription factors, including nuclear receptors, such as peroxisome proliferator-activated receptor alpha (Ppar-α) and liver X receptor alpha (LXRα). These transcription factors bind to the promoter region of the DCI gene and activate its transcription.
Post-translational modification of DCI includes phosphorylation, which is responsible for the activation or inactivation of the enzyme. For example, the activation of DCI by protein kinase C (PKC) leads to its translocation to the plasma membrane, where it is involved in the synthesis of eicosanoids. Additionally, the phosphorylation of DCI by protein kinase A (PKA) leads to its activation and increased catalytic activity.
DCI plays a crucial role in lipid metabolism, specifically in the elongation of fatty acids. It is involved in the synthesis of eicosanoids, which are important signaling molecules that regulate various physiological processes, including inflammation, pain, and blood pressure. Additionally, DCI is involved in the synthesis of phospholipids, which are crucial for cell membrane structure and function.
DCI is a crucial enzyme involved in lipid metabolism, playing a significant role in the synthesis and breakdown of fatty acids and lipids. This enzyme participates in the final step of fatty acid synthesis, converting enoyl-CoA into 3-hydroxyacyl-CoA, which is essential for the production of triglycerides and other lipid molecules.
Mutations in the DCI gene can lead to defects in lipid metabolism, affecting various physiological processes including energy homeostasis, inflammation, and cell signaling. These mutations can result in abnormal lipid levels, contributing to the development of metabolic disorders such as obesity, diabetes, and atherosclerosis.
In obesity, mutations in the DCI gene can lead to impaired fatty acid synthesis and lipid accumulation, contributing to the excessive storage of fat in adipose tissue. This, in turn, can result in insulin resistance and the development of type 2 diabetes.
In atherosclerosis, mutations in DCI can affect lipid metabolism in vascular cells, leading to lipid accumulation in the arterial wall and promoting the development of atherosclerotic plaques. These mutations can also impair the clearance of atherogenic lipoproteins from the bloodstream, further exacerbating the disease process.
Furthermore, DCI has been implicated in inflammation and immune responses, as it serves as a regulatory enzyme in the synthesis of eicosanoids, a class of lipid mediators involved in inflammation and pain signaling. Mutations in DCI can lead to imbalances in eicosanoid production, contributing to chronic inflammation and autoimmune disorders.
References:
Contact us today for a free consultation with the scientific team and discover how Creative Biogene can be a valuable resource and partner for your organization.
Inquiry
Copyright © Creative Biogene. All rights reserved.